Retrospective analysis of clinical and economic results of genotyping at-risk patients to guide narcotic detoxification

Abstract

Genotyping technology was used to guide narcotic detoxification efforts using Suboxone and other interventions and the clinical outcomes were determined. The patients were genotyped using the Proove Narcotic Risk Test using Real Time PCR TaqMan assay. Patients were enrolled in the NESP Suboxone narcotic detoxification program over a 90 day period with ongoing maintenance therapy based on genotype over two years. The subjects were chronic pain patients dependent on Rx narcotics [n=159] of which 82% [121 patients] had a successful outcome and of the 18% [27 patients] that were outside the category, 90% [24 patients] had a s successful initial outcome but due to subsequent medical problems or additional surgery by other healthcare professionals are now back on chronic Narcotic therapy. The remaining 3 relapsed for no medical reason the annual direct healthcare costs of these patients was reduced by $1.694M. The ROI was 0.28 or about $500,000 in the first year and 2.8 over two years. This compares favorably with other programs. Thus by genotyping patients and using the information to identify candidates for narcotic detoxification programs, the patient , physician and payer can benefit from improved clinical outcomes and cost savings over a multi-year period. This study was supported by a grant from Proove Biosciences Inc. Genotyping technology was used to guide narcotic detoxification efforts using Suboxone and other interventions and the clinical outcomes were determined. The patients were genotyped using the Proove Narcotic Risk Test using Real Time PCR TaqMan assay. Patients were enrolled in the NESP Suboxone narcotic detoxification program over a 90 day period with ongoing maintenance therapy based on genotype over two years. The subjects were chronic pain patients dependent on Rx narcotics [n=159] of which 82% [121 patients] had a successful outcome and of the 18% [27 patients] that were outside the category, 90% [24 patients] had a s successful initial outcome but due to subsequent medical problems or additional surgery by other healthcare professionals are now back on chronic Narcotic therapy. The remaining 3 relapsed for no medical reason the annual direct healthcare costs of these patients was reduced by $1.694M. The ROI was 0.28 or about $500,000 in the first year and 2.8 over two years. This compares favorably with other programs. Thus by genotyping patients and using the information to identify candidates for narcotic detoxification programs, the patient , physician and payer can benefit from improved clinical outcomes and cost savings over a multi-year period. This study was supported by a grant from Proove Biosciences Inc.